sildenafil inhibits the transporter function of ABCB1 and ABCG2 responsible for chemotherapy resistance, with a stronger effect on ABCB1. Our findings suggest a possible strategy to enhance the sensitivity of cancer cells to anti-cancer drugs by jointly using a clinically approved drug with known side effects and drug-drug interactions.
INTRODUCTION
of residues were adjusted to the dominant ionic forms at pH 7.4. Refined human ABCB1 homology model was further used to generate four different receptor grids by selecting QZ59-RRR (site-1) and QZ59-SSS (site-2) bound ligands, all amino acid residues known to contribute to verapamil binding (site-3) and two residues known to be common to three previous sites (site-4) as shown in supplemental Table 1 .
Docking protocol
All docking calculations were performed using the "Extra Precision" (XP) mode of Glide program v5.5 (Schrödinger, Inc., New York, NY, 2009) and the default parameters. The top scoring pose-ABCB1 complex was then subjected to energy minimization using Macromodel program v9.7 using the OPLS-AA force field (21) and used for graphical analysis. All computations were carried out on a Dell Precision 470n dual processor with the Linux OS (Red Hat Enterprise WS 4.0).
Statistical Analysis
All experiments were repeated at least three times and the differences were determined by using the Student's t-test. The statistical significance was determined at p < 0.05. 
RESULTS

Sildenafil sensitizes ABCB1-and ABCG2-overexpressing cells to chemotherapeutic drugs
To investigate the effect of sildenafil on ABC transporters-mediated MDR, we first examined the sensitivity of ABCB1-, ABCC1-, and ABCG2-mediated MDR cells to sildenafil. Interestingly, the results of the MTT assay showed that sildenafil did not inhibit the growth of any of the cell lines used in this study at concentrations up to 50 μM (data not shown). Next, we examined whether sildenafil could reverse ABCB1-mediated MDR. As shown in Table 1 , the ABCB1-overexpressing MDR cells KB-C2 and KB-V1 showed much higher IC 50 values to ABCB1 substrates colchicine, vinblastine, and paclitaxel than parent KB-3-1 cells did. Sildenafil dose-dependently decreased the IC 50 values of these drugs in KB-C2 and KB-V1 cells. Sildenafil at 2.5 μΜ was able to moderately reverse resistance to these three drugs. At 10 μM concentration, sildenafil further increased the sensitivity of cells, and its efficacy was comparable to that of the known ABCB1 inhibitor verapamil used at the same concentration (23). Neither sildenafil nor verapamil alter the cytotoxicity of these chemotherapeutic drugs in parental KB-3-1 cells. However, the IC 50 values of cisplatin, which is not a substrate of ABCB1 and exhibited the equal sensitivity to KB-3-1, KB-C2 and KB-V1 cells, were not affected by either sildenafil or verapamil in these three cells. Subsequently, the reversing effects of sildenafil on ABCC1-and ABCG2-mediated MDR were also determined. In the ABCC1-overexpressing KB-CV60 cells, sildenafil at 10 μΜ concentration had no significant reduction of the IC 50 value of vincristine, a known substrate of ABCC1 (data not shown). It has been reported that mutations at amino acid 482 in ABCG2 alter the substrate and antagonist specificity of ABCG2 (15, 24), therefore we examined the reversing effect of sildenafil on both wild-type (R482) and mutant (R482G and R482T) ABCG2 overexpressing cells. As shown in Table 2 , compared to parental MCF-7 cells, MCF-7/Flv1000 and MCF-7/AdVp3000 cells exhibited high levels of resistance to ABCG2 substrates flavopiridol, mitoxantrone and SN-38, but not to non-ABCG2 substrate cisplatin. Similarly, the IC 50 values for flavopiridol, mitoxantrone and SN-38 in S1-M1-80 were significantly higher than those in parental S1 cells. Sildenafil was able to slightly decrease the IC 50 values for flavopiridol, mitoxantrone and SN-38 in cells expressing wild-type or mutant ABCG2. At a concentration of 50 μM, sildenafil decreased IC 50 values for these three drugs in the ABCG2-expressing cell lines down to levels that were observed when cytotoxicity assays were performed in the presence of the known specific ABCG2 inhibitor FTC at 2.5 mM (16). However, the IC 50 values of these ABCG2 substrate drugs showed no significant difference in the parental cells or the S1/FLV5000 cells which does not express ABCG2 but also are resistant to flavopiridol in the presence or absence of sildenafil. Furthermore, when the non-ABCG2 substrate drug cisplatin was used, either sildenafil or FTC in any of the cell lines did not affect its IC 50 values. The similar phenomenon was observed in both wild-type or mutant ABCG2 transfected HEK293 cells (Table 3 ). 
DISCUSSION
In this study, we examined the effect of sildenafil on ABCB1-, ABCC1-and ABCG2-mediated MDR in cancer cells. Our data shows sildenafil has different effects on these three ABC transporters.
Cytotoxicity assays showed that sildenafil potently sensitized ABCB1 overexpressing cells to ABCB1 substrates colchicine, vinblastine and paclitaxel; mildly sensitized wild-type or mutant ABCG2-overexpressing cells to the ABCG2 substrates flavopiridol, mitoxantrone and SN-38.
However, sildenafil had no significant effect on sensitivity of ABCC1-overexpressing cells to its substrate vincristine. Furthermore, sildenafil did not sensitize any of the cells examined to cisplatin and had no effect on the sensitivity of any of the parental cell lines. These data suggest that the reversing ability of sildenafil could be specific to ABCB1 and ABCG2, although sildenafil appeared to have greater affinity for ABCB1 than for ABCG2. Consistent with cytotoxicity data, the results of drug accumulation studies showed that sildenafil significantly enhances the intracellular accumulation of paclitaxel in the ABCB1 overexpressing cells, and slightly enhances the intracellular accumulation of mitoxantrone and BODIPY-prazosin in cells overexpressing either wild type or mutant ABCG2. These results confirm that sildenafil has a greater affinity for ABCB1 than for ABCG2. In addition, the results of membrane vesicles transport experiments demonstrated that sildenafil directly inhibits ABCG2-mediated transport of E 2 17βG and methotrexate. The results of drug accumulation studies and membrane vesicles transport study indicate that sildenafil reverses ABCB1-and ABCG2-mediated MDR by directly inhibiting the drug-transport function of ABCB1 and ABCG2. Additionally, we also investigated the interaction of sildenafil with ABCB1 as well as with ABCG2 by using the Vi-sensitive ATPase assay and photoaffinity labeling with [
125 I]-IAAP.
Generally, the ATPase activity of ABC transporters is stimulated in the presence of transport substrates, and the fact that sildenafil powerfully stimulated the ATPase activity of ABCB1 and mildly stimulated the ATPase activity of ABCG2 suggests that it might potentially be a substrate of the 1280 residues, 15 residues represented by Glu74 (TM1), Asp77 (TM1), Glu86 (TM1/EC1), Asp87 (EC1), Asp97 (EC1), Asp100 (TM2), Glu108 (TM2), Glu109 (TM2), Asp110 (TM2), Glu325 (EC3), Asp743 (EC4), Asp744 (EC4), Glu746 (TM8/EC4), Glu972 (EC6/TM12), and Asp973 (TM12) were found to be located close to the membrane surface and are accessible from within the site-1 may provide selectivity for cationic amphipathic drug molecules through ionic interactions during their entry into the site-1 and these regions are akin to "portals" described by Aller et al in mouse Mdr3 protein (26).
Sildenafil is a highly selective inhibitor of cGMP-specific PDE5 and is widely used to treat erectile dysfunction and pulmonary arterial hypertension. The mechanism of action of sildenafil involves the protection of cGMP from degradation by PDE5. Sildenafil acts as a competitive binding agent of PDE5 with cGMP due to their similar structures, which results in increased levels of cGMP leading to vascular smooth muscle relaxation (vasodilation) and increased inflow of blood (30). However, in this study we did not examine and could not exclude the effects of sildenafil on the cGMP level. Although the concentrations of sildenafil used in the current study were a little higher than that of clinical patients and sufficient to block the PDE5 activity (31), we did not observe any significant effect on the growth and survival of cells. Up to now, several groups have evaluated the effect of sildenafil on cancer treatment due to the fact that some cancers showed higher level of 
reported that sildenafil in combination with doxorubicin induced apoptosis by upregulating caspase-3 and caspase-9 activity, by reducing the phosphorylation of Bad and expression of Bcl-xl in prostate cancer cells (36). In addition, sildenafil-doxorubicin combination reduced the tumor burden in mice prostate tumor xenograft model (36). Further study is mandated to ascertain the expression of ABCtransporters in Das et al. model, on the contrary, if apoptotic mechanism is involved in sildenafil induced sensitization of ABC-transporters needs to be determined. Based on these recent studies and our data, it is reasonable to suggest that sildenafil may have the potential to improve the chemotherapeutic outcome of cancer patients. Therefore, when exploring the combined use of sildenafil with anticancer drugs that are substrates of ABCB1 and ABCG2 in the future, its important to consider the pharmacokinetics of sildenafil and anticancer drugs, which may be affected by each other, potentially resulting in increased responses but also potentially increased adverse effects. This is indeed possible as ABCB1 and ABCG2 are found to be highly expressed in several normal tissues (1) , where the concentration and distribution of sildenafil and anticancer drugs might be altered in each other presence. Additionally, it has been reported that the most common side effects of sildenafil use included flushing, headache, dyspepsia, unintentional incomplete sexual arousal and palpitation, etc (37). Theoretically, by determining the structure activity relationship (SAR) of sildenafil on inhibiting the cGMP hydorlase and ABC transporters, it is possible to synthesize a better sildenafil analogue, which has the better MDR reversal effect without affecting the cGMP hydrolase activity.
In conclusion, the present study demonstrates that sildenafil reverses ABCB1-and ABCG2- 
